
|Videos|December 4, 2020
Pembrolizumab for first-line mRCC: Anecdotal evidence in real-world setting
Author(s)Urology Times staff
Arjun V. Balar, MD, discusses combination treatment with pembrolizumab (Keytruda) and axitinib (Inlyta) in the first-line setting for metastatic RCC.
Advertisement
In this video, Arjun V. Balar, MD, discusses the use of the immune checkpoint inhibitor pembrolizumab (Keytruda) for the treatment of metastatic renal cell carcinoma. Balar is associate professor of medicine at the NYU Grossman School of Medicine and genitourinary medical oncology program director at NYU Langone’s Perlmutter Cancer Center, New York.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves enfortumab vedotin plus pembrolizumab for MIBC
2
Study suggests tamsulosin deprescribing may be appropriate for select men with BPH
3
Amy E. Krambeck, MD, on choosing between CVAC and FANS for suction-based ureteroscopy
4
Trial launches of actinium (225Ac) rhPSMA-10.1 injection in mCRPC
5













